Search Results Label

Influenza is a common, highly contagious infection that can lead to life-threatening complications. Learn more about influenza and our cutting-edge vaccines.

https://www.seqirus.us/expertise/influenza

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.us/expertise

New Seqirus Data Published in Vaccines Highlight Effectiveness and Economic Benefit of Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) in the 2018/19 U.S. Influenza Season

https://www.seqirus.us/news/new-seqirus-data-published-in-vaccines-highlight-effectiveness

Company announces the publication of new real-world evidence on effectiveness of the MF59® adjuvanted, trivalent influenza vaccine (aTIV).

https://www.seqirus.us/news/new-rwe-flu-65-and-older

Seqirus is a world leader in developing and producing influenza vaccines. Learn more about how we work with our partners to protect the global community.

https://www.seqirus.us/products

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/seqirus-announces-late-breaking-data-at-idweek-2020

Seqirus Announces U.S. FDA Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older

https://www.seqirus.us/news/seqirus-announces-us-fda-approval-of-expanded-age-indication

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/seqirus-publishes-new-real-world-evidence

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/seqirus-presents-new-real-world-evidence-on-relative-effectiveness

Seqirus Presents Real-World Data for Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) at ESWI 2020

https://www.seqirus.us/news/seqirus-presents-real-world-data-for-cell-based-quadrivalent